T

Telomir Pharmaceuticals Inc
NASDAQ:TELO

Watchlist Manager
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Watchlist
Price: 4.3 USD -5.49% Market Closed
Market Cap: 127.3m USD
Have any thoughts about
Telomir Pharmaceuticals Inc?
Write Note

Profitability Summary

Telomir Pharmaceuticals Inc's profitability score is 27/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score
27/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Telomir Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-19.8m USD
Operating Income
-19.8m USD
Other Expenses
-9.4m USD
Net Income
-29.2m USD

Margins Comparison
Telomir Pharmaceuticals Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Telomir Pharmaceuticals Inc
NASDAQ:TELO
127.3m USD N/A N/A
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
747.7B USD
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
44%
35%
US
Johnson & Johnson
NYSE:JNJ
342.5B USD
28%
17%
US
Merck & Co Inc
NYSE:MRK
252.8B USD
34%
19%
CH
Roche Holding AG
SIX:ROG
215.4B CHF
32%
20%
UK
AstraZeneca PLC
LSE:AZN
170.5B GBP
21%
13%
CH
Novartis AG
SIX:NOVN
178.8B CHF
31%
35%
US
Pfizer Inc
NYSE:PFE
152.2B USD
22%
7%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Telomir Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Telomir Pharmaceuticals Inc
NASDAQ:TELO
127.3m USD
-2 230%
-919%
-1 513%
-877%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
747.7B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
342.5B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
252.8B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
215.4B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
170.5B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
178.8B CHF
45%
17%
24%
16%
US
Pfizer Inc
NYSE:PFE
152.2B USD
5%
2%
7%
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.